Corpus overview


Overview

MeSH Disease

COVID-19 (489)

Fever (101)

Pneumonia (94)

Death (80)

Hypertension (72)


HGNC Genes

SARS-CoV-2 proteins

ProteinN (7)

ProteinS (2)

ORF1ab (1)

ProteinS1 (1)


Filter

Genes
Diseases
SARS-CoV-2 Proteins
    displaying 41 - 50 records in total 498
    records per page




    Viral Shedding Time of SARS-CoV-2 and the Factors Involved: A Retrospective Observational Study

    Authors: Guixian Wu; Ling Lin; Susu He; Qian Chen; Xiaomai Wu; Shuangquan Yan; Yongpo Jiang; Weijia Pan; Dongqin Lv

    doi:10.21203/rs.3.rs-154418/v1 Date: 2021-01-25 Source: ResearchSquare

    Background: In December 2019, the discovery of the novel coronavirus was first reported in Wuhan, China, which subsequently and rapidly spread throughout the country and worldwide, resulting in a pandemic.After a year of intense research, our knowledge of the new coronaviruses has gradually improved; however, knowledge regarding the time of their complete clearance from the body and the factors influencing clearance are currently inadequate. Results: We conducted a retrospective observational study comprising 135 patients above the age of 18 years with a confirmed diagnosis of  COVID-19 MESHD pneumonia MESHD, who were admitted to the Public Health Center of Taizhou Hospital of Zhejiang Province, Zhejiang University from January 23, 2020, to March 11 HGNC, 2020. The findings regarding the duration of the infection from the time of onset to the time of being asymptomatic (whichever was observed first) indicated that novel coronaviruses were cleared from the respiratory tract in a maximum of 84 days and a minimum of 1 day with a median clearance time (quartile) of 20 (13, 30) days. Moreover, viruses were cleared from the digestive tract in a maximum of 72 days and a minimum of 5 days with a median clearance time (quartile) of 25 (20.75, 31) days. The viral shedding time of SARS in the digestive tract was found to be longer than that in the respiratory tract (p = 0.03). Severe disease (P < 0.001), advanced age (P < 0.001), lymphopenia MESHD (P = 0.01) and elevated CRP HGNC (P = 0.036) were significantly associated with longer clearance time in the respiratory tract. Gender (P = 0.754), novel coronavirus antibodies (P = 0.75), and antibiotic use (P = 0.093) were not associated with the time span required for the novel coronavirus to be cleared from the respiratory tract. Conclusions: Independent risk factors for the longer clearance time of novel coronaviruses in the digestive tract versus that in the respiratory tract were compared. Severe disease MESHD, advanced age, lymphopenia MESHD, and elevated CRP HGNC were determined to be factors prolonging the clearance of novel coronaviruses.

    Computation Tomography (CT)-Based Evaluation of Temporal Changes in Lung Abnormalities MESHD During the Recovery Stage in COVID-19 MESHD In-Hospital Patients

    Authors: Yanjing Wang; Robert Lakin; Nan Jiang; Bo Yang; Daoyuan Si; Mei Ding; Guohui Liu; Peiyong Ma; Han Wu; Xiaoyu Ge; Bo Yu; Yuquan He; Jiayu Li; Ping Yang; Huan Sun; Lin Liu

    doi:10.21203/rs.3.rs-153806/v1 Date: 2021-01-23 Source: ResearchSquare

    Objectives: To assess the late phase CT changes of COVID-19 MESHD patients, and figure out factors predicting lung abnormality MESHD in late phase.Methods: We conducted a retrospective study on 42 patients (14 males, 28 females; age 65±10 years) with COVID-19 MESHD admitted between February 7, 2020 and March 27, 2020. Only patients with at least 3 CT scans taken at least 3 weeks after initial symptom onset were included in the study. CT images were analyzed by 2 independent radiologists using different scoring: (1) area-based scoring ( ABS MESHD); and (2) intensity-weighted scoring (IWS). Temporal changes in the average lung lesion were evaluated by averaged area under the curve (AUC) of the CT score-time curve. Correlations between averaged AUCs and clinical characteristics were determined. Results: Temporal changes in lung abnormalities MESHD during recovery (weeks 3 through 8) of CT findings using the ABS system were variable (P=0.934). By contrast, the IWS system detected more subtle changes in lung abnormalities MESHD during the late phase of recovery in COVID-19 MESHD patients, with consistent week-to-week relative reductions in IWS (P=0.025). In assessing the correlation between averaged AUCs and clinical characteristics, strong relationships were observed with D-dimer and C-reactive protein HGNC ( CRP HGNC) levels on admission, with hazard ratios (HR)(95%CI) of 5.32 (1.25-22.6)(P=0.026) and 1.05 (1.10-1.09)(P=0.017), respectively. Conclusion: Our results suggest an intensity-weighted rather than area-based scoring system is more sensitive to detect subtle temporal CT changes in COVID-19 MESHD, with D-dimer and CRP HGNC levels on admission being predictive of the time course of late phase recovery from the disease.

    Predictors of Mortality in COVID-19 MESHD Patients at Kinshasa Medical Center and A Survival Analysis: A Retrospective Cohort Study

    Authors: Yannick MAYAMBA NLANDU; Danny Mafuta; Junior Sakaji; Melinda Brecknell; Yannick Engole; Jessy Abatha; Jean-Robert Nkumu; Aliocha Nkodila; Marie-France Mboliassa; Olivier Tuyinama; Dauphin Bena; Yves Mboloko; Patrick Kobo; Patrick Boloko; Joseph Tshangu; Philippe Azika; Jean-Pierre Kanku; Pally Mafuta; Magloire Atantama; Jean-Michel Mavungu; Rosita Kitenge; Asma Sehli; Karel Van Eckout; Cathy Mukuku; Léo Bergeret; David Benchetritt; Golan Kalifa; Ahmed Rodolphe; Justine Bukabau

    doi:10.21203/rs.3.rs-153818/v1 Date: 2021-01-23 Source: ResearchSquare

    BackgroundDespite it being a global pandemic, there is little research examining the clinical features of severe COVID-19 MESHD in sub-Saharan Africa. This study aims to identify predictors of mortality in COVID-19 MESHD patients in an African setting.MethodsIn this retrospective, observational, cohort study carried out at the Kinshasa Medical Centre (KMC) between March 10 HGNC, 2020 and July 10, 2020, we included all adult inpatients (≥18 years old) with a laboratory diagnosis by PCR of COVID-19 MESHD. The end point of the study was survival to discharge (time-to-death).The study population was dichotomized into survivors and non-survivors group. Kaplan-Meier plot was used for survival analyses. The Log-Rank test was employed to compare the survival curves. Predictors of mortality were identified by Cox regression models. The significance level of P value was set at 0.05.Results106 patients (mean age 55.6±13.2 years old, 80.2% were male), were included in this study, of whom 34 (32 %) died during their hospitalisation. The main Complications of the patients included ARDS in 59/66 (89.4%) patients, coagulopathy MESHD in 35/93 (37.6%) patients, acute cardiac injury MESHD in 24/98 (24.5%) patients, AKI in 15/74 (20.3%) patients and secondary infection MESHD in 12/81 (14.8%) patients. The independent predictors of mortality were found to be age ≥ 65 years [aHR 2.49; 95% CI: 1.53-5.69], AKI stage 3 [aHR 2.51; 95% CI: 1.33-6.80], proteinuria MESHD [aHR 2.60; 95% CI: 1.40-6.42], CRP HGNC >150 mg/L [aHR 2.75; 95% CI: 1.29-3.68] and procalcitonin (PCT) > 0.5 ng/ml [aHR 3.20; 95% CI: 1.70-7.49].The median survival time of the entire group was 12 days. The cumulative survival rate of COVID-19 MESHD patients was 86.9%, 65.0% and 19.9% respectively at 5, 10 and 20 days. Levels of creatinine (p= 0.012), were clearly elevated in non-survivors compared with survivors throughout the clinical course and increased deterioration.ConclusionThe results from this study demonstrated that an advanced age, proteinuria MESHD, AKI and raised CRP HGNC and PCT offered a worse prognosis in COVID-19 MESHD patients. In addition, serum levels of creatinine significantly rose during admission in the non-survivor group compared with those who survived to discharge.

    Development and validation of a predictive model for critical illness MESHD in adult patients requiring hospitalization for COVID-19 MESHD

    Authors: Neha Paranjape; Lauren Staples; Christina Stradwick; Herman Ray; Ian Saldanha

    doi:10.1101/2021.01.22.21250289 Date: 2021-01-22 Source: medRxiv

    Background: Identifying factors that can predict severe disease in patients needing hospitalization for COVID-19 MESHD is crucial for early recognition of patients at greatest risk. Objective: (1) Identify factors predicting intensive care unit (ICU) transfer and (2) develop a simple calculator for clinicians managing patients hospitalized with COVID-19 MESHD. Methods: A total of 2,685 patients with laboratory-confirmed COVID-19 MESHD admitted to a large metropolitan health system in Georgia, USA between March and July 2020 were included in the study. Seventy-five percent of patients were included in the training dataset (admitted March 1 HGNC to July 10). Through multivariable logistic regression, we developed a prediction model (probability score) for ICU transfer. Then, we validated the model by estimating its performance accuracy (area under the curve [AUC]) using data from the remaining 25% of patients (admitted July 11 to July 31). Results: We included 2,014 and 671 patients in the training and validation datasets, respectively. Diabetes mellitus MESHD, coronary artery disease MESHD, chronic kidney disease MESHD, serum C-reactive protein HGNC, and serum lactate dehydrogenase were identified as significant risk factors for ICU transfer, and a prediction model was developed. The AUC was 0.752 for the training dataset and 0.769 for the validation dataset. We developed a free, web-based calculator to facilitate use of the prediction model (https://icu covid19 MESHD.shinyapps.io/ICU COVID19 MESHD/). Conclusion: Our validated, simple, and accessible prediction model and web-based calculator for ICU transfer may be useful in assisting healthcare providers in identifying hospitalized patients with COVID-19 MESHD, who are at high risk for clinical deterioration. Triage of such patients for early aggressive treatment can impact clinical outcomes for this potentially deadly disease.

    Impact of Pulse D Therapy on The Inflammatory Markers in Patients With COVID-19 MESHD.

    Authors: Dr. Maheshwar Lakkireddy; Dr. Srikanth Goud Gadiga; Dr. R.D. Malathi; Dr. Madhu Latha Karra; Dr. I S S V Prasad Murthy Raju; Dr Ragini; Dr. Sangeetha Chinapaka; Dr. Sai Baba KSS; Dr. Manohar Kandakatla

    doi:10.21203/rs.3.rs-152494/v1 Date: 2021-01-21 Source: ResearchSquare

    Introduction: COVID 19 is known to cause immune dysregulation MESHD and vitamin D is a known immunomodulator. This study aims to objectively investigate the impact of Pulse D therapy in reducing the inflammatory markers of COVID-19 MESHD. Materials/ Methods: Consented COVID-19 MESHD patients with hypovitaminosis D were evaluated for inflammatory markers (N/L ratio, CRP HGNC, LDH, IL6 HGNC, Ferritin) along with vitamin D on 0th day and 9th / 11th day as per their respective BMI category. Subjects were randomised into VD and NVD groups. VD group received Pulse D therapy (targeted daily supplementation of 60,000 IUs of vitamin D for 8 or 10 days depending upon their BMI) in addition to the standard treatment. NVD group received standard treatment alone. Differences in the variables between the two groups were analysed for statistical significance. Results: Eighty seven out of one hundred and thirty subjects have completed the study (VD:44, NVD:43). Vitamin D level has increased from 15.65 ± 5.54 ng/ml to 88.96 ± 31.55 ng/ml after Pulse D therapy in VD group and highly significant (p<0.01) reduction of all the measured inflammatory markers was noted. Reduction of markers in NVD group was insignificant (p>0.05) . The difference in the reduction of markers between the groups (NVD vs VD) was highly significant (p<0.01). Conclusions: Therapeutic improvement in vitamin D to 80-100 ng/ml has significantly reduced the inflammatory markers associated with COVID-19 MESHD without any side effects. Hence, adjunctive Pulse D therapy can be added safely to the existing treatment protocols of COVID-19 MESHD for improved outcomes. 

    Clinical utility of Corona Virus Disease MESHD-19 serum IgG, IgM, and neutralizing antibodies and inflammatory markers

    Authors: Ernst J Schaefer; Florence Comite; Latha Dulipsingh; Maxine Lang; Jessica Jimison; Martin M Grajower; Nathan E Lebowitz; Andrew S Geller; Margaret R Diffenderfer; Lihong He; Gary Breton; Michael L Dansinger; Ben Saida; Chong Yuan

    doi:10.1101/2021.01.19.21249604 Date: 2021-01-20 Source: medRxiv

    Most deaths MESHD from severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection MESHD occur in older subjects. We assessed age effects and clinical utility of serum SARS-CoV-2 immunoglobulin G (IgG), immunoglobulin M (IgM), and neutralizing antibodies and serum inflammatory markers. Serum IgG, IgM, and neutralizing antibody levels were measured using chemiluminescence assays from Diazyme (Poway, CA), while serum interleukin-6 HGNC ( IL-6 HGNC), C reactive protein HGNC ( CRP HGNC), and ferritin were measured with immunoassays obtained from Roche (Indianapolis, IN). In 79,005 subjects, IgG and IgM levels were positive ([≥]1.0 arbitrary units [AU]/mL) in 5.29% and 3.25% of subjects, respectively. In antibody positive subjects, median IgG levels were 3.93 AU/mL if <45 years of age, 10.18 AU/mL if 45-64 years of age, and 10.85 AU/mL if [≥]65 years of age (p<0.0001). In SARS-CoV-2 RNA positive cases, family members and exposed subjects (n=1,111), antibody testing was found to be valuable for case finding, and persistent IgM levels were associated with chronic symptoms. In non-hospitalized and hospitalized subjects assessed for SARS-CoV-2 RNA (n=278), median IgG levels in AU/mL were 0.05 in negative subjects (n=100), 14.83 in positive outpatients (n=129), and 30.61 in positive hospitalized patients (n=49, p<0.0001). Neutralizing antibody levels correlated significantly with IgG (r=0.875; p<0.0001). Two or more of the criteria of IL-6 HGNC [≥]10 pg/mL, CRP HGNC [≥]10 mg/L, and/or IgM >1.0 AU/mL occurred in 97.7% of inpatients versus 1.8% of outpatients (>50-fold relative risk, C statistic 0.986, p<0.0001). Our data indicate that: 1) IgG levels are significantly higher in positive older subjects, possibly to compensate for decreased cellular immunity with aging; 2) IgG levels are important for case finding in family clusters; 3) IgG levels are significantly correlated with neutralizing antibody levels; 4) persistently elevated IgM levels are associated with chronic disease MESHD; and 5) markedly elevated IL-6 HGNC, hs- CRP HGNC, and/or positive IgM accurately identify SARS-CoV-2 RNA positive subjects requiring hospitalization.

    NEWS2 and laboratory predictors correlated with clinical deterioration in hospitalised patients with COVID-19 MESHD

    Authors: Gulsah Tuncer; Serkan Surme; Osman Faruk Bayramlar; Hatice Kubra Karanalbant; Betul Copur; Meltem Yazla; Esra Zerdali; Inci Yilmaz-Nakir; Ayse Ruhkar Kurt-Cinar; Ahmet Buyukyazgan; Hatice Balli; Yesim Kurekci; Serap Simsek-Yavuz; Mehmet Mesut Sonmez; Gonul Sengoz; Filiz Pehlivanoglu

    doi:10.1101/2021.01.17.21249878 Date: 2021-01-20 Source: medRxiv

    Background: We aimed to determine prognostic values of NEWS2 and laboratory parameters during the first week of COVID-19 MESHD. Methods: All adult patients who were hospitalized for a confirmed COVID-19 MESHD between the 11th of March and the 11th of May 2020 were retrospectively included. To evaluate the factors in prognosis which are admission to intensive care unit (ICU) and in-hospital death, univariate logistic regression analysis was performed at admission (D0), at day-3 (D3), day-5 (D5), and day-7 (D7). Additionally, receiver operating characteristic (ROC) analyses were performed. Results: Overall, 611 patients were included. Clinical deterioration was observed in 79 (12.9%) patients during hospitalisation, 36 (5.9%) during the first three days, 54 (8.8%) during the first five days, and 62 (10.1%) during the first week of hospitalisation. Our results showed that NEWS2, procalcitonin, neutrophil/lymphocyte ratio (NLR), and albumin were the best predictors for clinical deterioration at D0, D3, D5, and D7. Procalcitonin had the highest odds ratio for clinical deterioration on all days in univariate analysis. ROC analyses showed that NEWS2 at D7, procalcitonin at D5, albumin at D7, and NLR at D5 had highest AUC values. Additionally, we detected a strong correlation between NEWS2 and laboratory parameters including neutrophil, lymphocyte, NLR, platelet/lymphocyte ratio, CRP HGNC, procalcitonin, ferritin, and urea on all days. Conclusion: This study provides a list of several laboratory parameters correlated with NEWS2 and potential predictors for ICU admission or in-hospital death during the clinical course of COVID-19 MESHD. Dynamic monitoring of NEWS2 and laboratory parameters is vital for improving clinical outcomes.

    Hyperinflammatory conditions, gender differences and mortality in Indian COVID-19 MESHD patients

    Authors: Fouzia Shoeb; Imran Hussain; Gazala Afrin; Shagufta T Mufti; Syed T Raza; Farzana Mahdi

    doi:10.1101/2021.01.19.21250134 Date: 2021-01-20 Source: medRxiv

    PurposeEvidence suggests that COVID-19 MESHD induces hyperinflammatory conditions and causes relatively more deaths MESHD in males than females. The purpose of this study was to analyze gender differences associated with various hyperinflammatory conditions (HIC) and mortality in the Indian COVID-19 MESHD patients MethodsThis study was conducted at the Eras Lucknow Medical College and Hospital (ELMCH), ERA HGNC University, which is located in the northern part of India. Starting from July 4, 2020 till December 3, 2020 a total of 2997 patients were treated at ELMCH. We randomly collected blood samples from 150 severe COVID-19 MESHD patients (required oxygen) between August 10 and September 15, 2020 for analyzing the following HIC and associated laboratory markers: hyperferritinaemia (serum ferritin), hematological dysfunctions MESHD ( lymphocytopenia MESHD and neutrophil to lymphocyte ratio), cytokinaemia ( C-reactive protein HGNC), coagulopathy MESHD (D-dimer), liver inflammation MESHD (aspartate aminotransferase), renal inflammation MESHD (blood urea and creatinine), and hyperglycemia MESHD (random blood glucose). The threshold values/cut off limits of these laboratory markers used for analyzing the risk of mortality in male and female COVID-19 MESHD patients were set according to the scale validated recently by Webb et al, (2020). ResultsIn the above cohort of consecutively admitted COVID-19 MESHD patients, analysis of various HIC revealed hyperferritinaemia (odd ratio: 2.9, 95% CI 1.4-6.0), hematological dysfunctions MESHD (odd ratio: 2.10, 95% CI 1.0-4.2), hepatic inflammation MESHD (odd ratio: 2.0, 95% CI 0.52-7.40), and coagulopathy MESHD (odd ratio: 1.5, 95% CI 1.50, 95% CI 0.50-4.60) were more prevalent and sever in male COVID-19 MESHD patients. Approximately 86% male to 64% female COVID-19 MESHD patients developed lymphocytopenia MESHD. Regarding mortality, while hyperferritinaemia (odd ratio: 1.70, 95% CI 0.37-7.43) and cytokinaemia (odd ratio: 1.60, 95% CI 0.37 -7.30) were strongly associated with mortality in male COVID-19 MESHD patients, coagulopathy MESHD (odd ratio: 3.30, 95% CI 0.31-35), and hematological dysfunctions MESHD (odd ratio: 1.70, 95% CI 0.27-10) were more commonly associated with mortality in female COVID-19 MESHD patients. Nearly 80% male and female COVID-19 MESHD patients, who died had developed [≥]2 criteria of HIS criteria. Chronic renal disease MESHD was associated with more deaths in female than male COVID-19 MESHD patients (odd ratio: 2.0, 95% CI 0.54 - 7.4). While the mortality proportion was slightly higher in male (6.3%) than female (4.5%) COVID-19 MESHD patients, survival curves of the two genders were not different (hazard ratio: 1.02, 95% CI 0.71-1.40, P = 0. 953). ConclusionDistinct HIC were associated with the severity, and mortality in male and female COVID-19 MESHD patients. Coagulopathy and renal injury MESHD were detrimental, specifically, for female COVID-19 MESHD patients. The overall mortality proportion was around 5.3%. The above results suggest that gender differences associated with COVID-19 MESHD severity and mortality arise due to differences in various HIC. These results may help in developing personalized or gender based treatments for COVID-19 MESHD patients.

    Clinical Features and Death Risk Factors in COVID-19 MESHD Patients with Cancer MESHD: A Retrospective Study

    Authors: Yi Zhou; Qiao Yang; Jun Ye; Xiaocheng Wu; Xianhua Hou; Yimei Feng; Bangyu Luo; Jixi Li; Guangrong Yang; Lingchen Li; Xiu Yang; Bin Wang; Songtao Zhao; Li Li; Qi Li; Zi Xu; Hao Wu; Jianguo Sun

    doi:10.21203/rs.3.rs-149362/v1 Date: 2021-01-17 Source: ResearchSquare

    Purpose: Coronavirus disease 2019 MESHD ( COVID-19 MESHD) has spread around the world. This retrospective study aims to analyze the clinical features of COVID-19 MESHD patients with cancer MESHD and identify death outcome related risk factors.Methods: From February 10th to April 15th, 2020, 103 COVID-19 MESHD patients with cancer MESHD were enrolled. Difference analyses were performed between severe and non-severe patients. A propensity score matching analysis, including 103 COVID-19 MESHD patients with cancer MESHD and 206 matched non-cancer COVID-19 MESHD patients were performed. Next, we identified death related risk factors and developed a nomogram for predicting the probability.Results: In 103 COVID-19 MESHD patients with cancer MESHD, the main cancer MESHD categories were breast cancer MESHD, lung cancer MESHD and bladder cancer MESHD. Compared to non-severe patients, severe patients had a higher median age, and a higher proportion of smokers, diabetes MESHD, heart disease MESHD and dyspnea MESHD. In addition, most of the laboratory results between two groups were significant different. PSM analysis found that the proportion of dyspnea MESHD was much higher in COVID-19 MESHD patients with cancer MESHD. The severity incidence in two groups were similar, while a much higher mortality was found in COVID-19 MESHD patients with cancer MESHD compared to that in COVID-19 MESHD patients without cancer MESHD (11.7% vs. 4.4%, P = 0.028). Furthermore, we found that neutrophil-to-lymphocyte ratio (NLR) and C-reactive protein HGNC ( CRP HGNC) were related to death outcome. And a nomogram based on the factors was developed.Conclusion: In COVID-19 MESHD patients with cancer MESHD, the clinical features and laboratory results between severe group and non-severe group were significant different. NLR and CRP HGNC were the risk factors that could predict death outcome.

    Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection MESHD

    Authors: Andrew Hill; Ahmed Abdulamir; Sabeena Ahmed; Asma Asghar; Olufemi Emmanuel Babalola; Rabia Basri; Carlos Chaccour; Aijaz Zeeshan Khan Chachar; Abu Tauib Mohammed Chowdhury; Ahmed Elgazzar; Leah Ellis; Jonathan Falconer; Anna Garratt; Basma Hany; Hashim A Hashim; Wasim Ul Haque; Arshad Hayat; Shuixiang He; Ramin Jamshidian; Wasif Ali Khan; Ravi Kirti; Alejandro Krolewiecki; Carlos Lanusse; Jacob Levi; Reaz Mahmud; Sermand Ahmed Mangat; Kaitlyn McCann; Anant Mohan; Mortezza Shakshi Niaee; Nurullah Okumus; Victoria Pilkington; Chinmay Saha Podder; Ambar Qavi; Houssam Raad; Mohammaed Sadegh Rezai; Surapaneni Sasank; Veerapaneni Spoorthi; Tejas Suri; Junzheng Wang; Hannah Wentzel

    doi:10.21203/rs.3.rs-148845/v1 Date: 2021-01-16 Source: ResearchSquare

    Ivermectin is an antiparasitic drug being investigated for repurposing to SARS-CoV-2. In-vitro, ivermectin showed limited antiviral activity and a COVID-19 MESHD animal model demonstrated pathological benefits but no effect on viral RNA. This meta-analysis investigated ivermectin in 18 randomized clinical trials (2282 patients) identified through systematic searches of PUBMED, EMBASE, MedRxiv and trial registries. Ivermectin was associated with reduced inflammatory markers ( C-Reactive Protein HGNC, d-dimer and ferritin) and faster viral clearance by PCR. Viral clearance was treatment dose- and duration-dependent. In six randomized trials of moderate or severe infection, there was a 75% reduction in mortality (Relative Risk=0.25 [95%CI 0.12-0.52]; p=0.0002); 14/650 (2.1%) deaths on ivermectin; 57/597 (9.5%) deaths in controls) with favorable clinical recovery and reduced hospitalization. Many studies included were not peer reviewed and meta-analyses are prone to confounding issues. Ivermectin should be validated in larger, appropriately controlled randomized trials before the results are sufficient for review by regulatory authorities.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.